
Opinion|Videos|January 24, 2024
REACH3: Ruxolitinib in Steroid Refractory cGvHD
Author(s)Robert Zeiser, MD, Nelson J. Chao, MD
Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5






































